Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5984 USD | +3.00% | -8.08% | -27.18% |
May. 30 | Brookline Capital Initiates Forte Biosciences at Buy Rating With $4 Price Target | MT |
May. 13 | Forte Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Number of employees: 9
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paul Wagner
CEO | Chief Executive Officer | 53 | 16-12-31 |
Anthony Riley
DFI | Director of Finance/CFO | 57 | 20-02-29 |
Chief Operating Officer | - | 20-09-30 | |
Steven J. Ruhl
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Gryska
BRD | Director/Board Member | 68 | 23-01-09 |
Steven Kornfeld
BRD | Director/Board Member | 56 | 20-05-31 |
Director/Board Member | 65 | 22-05-11 | |
Barbara Finck
BRD | Director/Board Member | 77 | 22-03-15 |
Paul Wagner
CEO | Chief Executive Officer | 53 | 16-12-31 |
Donald Williams
BRD | Director/Board Member | 65 | 20-05-31 |
Scott Brun
BRD | Director/Board Member | 56 | 22-11-09 |
Director/Board Member | 66 | 20-05-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 36,442,380 | 29,201,216 ( 80.13 %) | 0 | 80.13 % |
Company contact information
Sector
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-27.18% | 21.15M | |
+16.73% | 121B | |
+13.04% | 107B | |
-5.80% | 24.82B | |
+1.69% | 22.48B | |
-10.09% | 18.32B | |
-40.52% | 16.33B | |
-14.00% | 15.31B | |
+1.18% | 14.08B | |
+24.18% | 11.74B |
- Stock Market
- Equities
- FBRX Stock
- Company Forte Biosciences, Inc.